Healthcare provider profile · identity verified

Maria Sofia Irizarry Zapata, MD

Internal Medicine · MIAMI, FL · NPI 1124511027

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	462	191
Losartan Potassium	Losartan Potassium	399	139
Gabapentin	Gabapentin	374	120
Benzonatate	Benzonatate	338	333
Lisinopril	Lisinopril	248	87
Azithromycin	Azithromycin	241	239
Metformin Hcl	Metformin Hcl	234	87
Famotidine	Famotidine	211	117
Omeprazole	Omeprazole	194	80
Rosuvastatin Calcium	Rosuvastatin Calcium	183	65
Amlodipine Besylate	Amlodipine Besylate	182	78
Levothyroxine Sodium	Levothyroxine Sodium	176	73
Xarelto	Rivaroxaban	175	37
Metoprolol Succinate	Metoprolol Succinate	174	72
Fluticasone Propionate	Fluticasone Propionate	164	119
Mupirocin	Mupirocin	142	131
Tamsulosin Hcl	Tamsulosin Hcl	136	54
Furosemide	Furosemide	126	65
Doxycycline Monohydrate	Doxycycline Monohydrate	123	122
Sildenafil Citrate	Sildenafil Citrate	121	37
Albuterol Sulfate Hfa	Albuterol Sulfate	119	50
Hydrochlorothiazide	Hydrochlorothiazide	117	54
Prednisone	Prednisone	110	109
Metoprolol Tartrate	Metoprolol Tartrate	107	41
Celecoxib	Celecoxib	95	92
Glipizide	Glipizide	94	33
Pantoprazole Sodium	Pantoprazole Sodium	90	43
Carvedilol	Carvedilol	86	34
Clopidogrel	Clopidogrel Bisulfate	86	36
Vitamin D2	Ergocalciferol (Vitamin D2)	82	56
Simvastatin	Simvastatin	76	28
Comfort Ez Pen Needle	Pen Needle, Diabetic	72	23
Diclofenac Sodium	Diclofenac Sodium	71	44
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	71	17
Donepezil Hcl	Donepezil Hcl	70	30
Hydrocortisone	Hydrocortisone	70	34
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	68	68
Ciprofloxacin Hcl	Ciprofloxacin Hcl	68	68
Synjardy Xr	Empagliflozin/Metformin Hcl	67	21
Alendronate Sodium	Alendronate Sodium	65	30
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	65	48
Trazodone Hcl	Trazodone Hcl	61	25
Metformin Hcl Er	Metformin Hcl	54	18
Lactulose	Lactulose	53	26
Montelukast Sodium	Montelukast Sodium	53	23
Methylprednisolone	Methylprednisolone	51	51
Lidocaine Hcl Viscous	Lidocaine Hcl	50	50
Tizanidine Hcl	Tizanidine Hcl	49	49
Naproxen	Naproxen	48	48
Fenofibrate	Fenofibrate	47	16
Atenolol	Atenolol	46	20
Meloxicam	Meloxicam	45	44
Cephalexin	Cephalexin	43	42
Eliquis	Apixaban	43	suppressed
Folic Acid	Folic Acid	43	24
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	43	12
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	43	43
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	42	suppressed
Ondansetron Hcl	Ondansetron Hcl	42	41
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	42	suppressed
Ezetimibe	Ezetimibe	41	13
Warfarin Sodium	Warfarin Sodium	41	suppressed
Ibuprofen	Ibuprofen	40	33
Memantine Hcl	Memantine Hcl	40	15
Mometasone Furoate	Mometasone Furoate	39	35
Mirtazapine	Mirtazapine	36	15
Allopurinol	Allopurinol	34	11
Glipizide Er	Glipizide	34	13
Hydralazine Hcl	Hydralazine Hcl	34	15
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	34	suppressed
Levofloxacin	Levofloxacin	33	33
Nifedipine Er	Nifedipine	33	15
Baclofen	Baclofen	29	22
Clonidine Hcl	Clonidine Hcl	28	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	28	suppressed
Spironolactone	Spironolactone	28	11
Loperamide	Loperamide Hcl	26	25
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	26	26
Insulin Aspart Flexpen	Insulin Aspart	25	suppressed
Irbesartan	Irbesartan	25	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	suppressed
Sertraline Hcl	Sertraline Hcl	25	suppressed
Glimepiride	Glimepiride	24	11
Metronidazole	Metronidazole	24	24
Pregabalin	Pregabalin	24	suppressed
Acyclovir	Acyclovir	23	20
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Nyamyc	Nystatin	22	11
Azelastine Hcl	Azelastine Hcl	21	20
Erythromycin	Erythromycin Base	21	20
Jardiance	Empagliflozin	21	11
Triamcinolone Acetonide	Triamcinolone Acetonide	21	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	20	18
Dutasteride	Dutasteride	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Neomycin-Polymyxin-Hc	Neomycin/Polymyxin B/Hydrocort	18	17
Ofloxacin	Ofloxacin	18	18
Olmesartan Medoxomil	Olmesartan Medoxomil	18	suppressed
Bumetanide	Bumetanide	17	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Entresto	Sacubitril/Valsartan	17	suppressed
Pentoxifylline	Pentoxifylline	17	suppressed
Topiramate	Topiramate	17	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Clonazepam	Clonazepam	15	suppressed
Creon	Lipase/Protease/Amylase	15	suppressed
Insulin Glargine Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	15	suppressed
Temazepam	Temazepam	15	suppressed
Theophylline Er	Theophylline Anhydrous	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Methocarbamol	Methocarbamol	14	suppressed
Oseltamivir Phosphate	Oseltamivir Phosphate	14	12
Finasteride	Finasteride	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Potassium Chloride	Potassium Chloride	13	12
Buspirone Hcl	Buspirone Hcl	12	suppressed
Cefdinir	Cefdinir	12	12
Diltiazem Hcl	Diltiazem Hcl	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Tramadol Hcl	Tramadol Hcl	12	12
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Ciclopirox	Ciclopirox	11	suppressed
Glyxambi	Empagliflozin/Linagliptin	11	suppressed
Lubiprostone	Lubiprostone	11	suppressed
Mesalamine	Mesalamine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error